Genomic tests for persistence PSA after radical prostatectomy: smoke and mirrors or new effective tools for the clinical decision-making?

Minerva Urol Nephrol. 2023 Dec;75(6):776-779. doi: 10.23736/S2724-6051.23.05637-9.

Authors

Enrico Checcucci¹, Christoph Oing², Pasquale Rescigno^{3

2}

Affiliations

¹ Department of Surgery, FPO-IRCCS Candiolo Cancer Institute, Candiolo, Turin, Italy - checcu.e@hotmail.it.
² Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
³ Department of Surgery, FPO-IRCCS Candiolo Cancer Institute, Candiolo, Turin, Italy.

PMID: 38126291
DOI: 10.23736/S2724-6051.23.05637-9

No abstract available

Publication types

Comment

MeSH terms

Clinical Decision-Making
Genomics
Humans
Male
Prostate*
Prostate-Specific Antigen*
Prostatectomy

Substances

Prostate-Specific Antigen